Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€4.74

€4.74

-1.150%
-0.085
-1.150%
€8.50

€8.50

 
Latest predictions
€8.00
18.01.21
buy
-
18.12.20
buy
-
28.10.20
€5.00
16.03.20
buy
-
11.01.20
buy
€12.00
20.09.19
buy
Your prediction

Medigene AG Stock

A loss of -1.150% shows a downward development for Medigene AG.
We see a rather positive sentiment for Medigene AG with 7 Buy predictions and 1 Sell predictions.
As a result the target price of €8.00 shows a very positive potential of 68.955% compared to the current price of €4.74 for Medigene AG.
For the coming years our community has positive and negative things to say abot the Medigene AG stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.

Pros and Cons of Medigene AG in the next few years

Pros
1
Could be worthwhile Investment >10% per year
1
Innovative
Cons
1
Higher risks for its business
1
Dependend from some customers or products

Performance of Medigene AG vs. its peers

Security Change (%) 1w 1m 1y YTD 3y 5y
Medigene AG -1.150% 3.724% 28.320% -21.671% 33.946% -68.007% -37.118%
B.R.A.I.N. Biotechnology Research and Information Network AG -0.450% -6.667% -2.032% -12.412% -4.194% -68.147% -
Affimed N.V. -5.470% -5.938% -0.852% 105.134% 10.119% - -
Formycon AG -0.320% -0.639% -3.715% 93.168% 17.358% 90.798% 226.167%

Comments

Buy Medigene AG

Buy Medigene AG

Sell Medigene AG

Other discussions about Medigene AG Stock

Trading Medigene AG

Trading Medigene AG

New thread Forum

News

Medigene AG: Medigene provides Q3 2020 update

Business news for the stock market

 

Planegg/Martinsried (12.11.2020) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development

Medigene AG: Oral and poster presentations on Medigene's clinical research at ASH conference

Business news for the stock market

 

Planegg/Martinsried (05.11.2020) - 5 November 2020. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing

Medigene AG: Medigene and Cytovant enter into service agreement for DC vaccine manufacturing process development

 

Planegg/Martinsried (19.10.2020) - Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for the

Medigene AG: Three Medigene poster presentations at SITC Annual Meeting

 

Planegg/Martinsried (15.10.2020) - Scientists of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell

Medigene AG: Medigene expands patent protection of its technologies

 

Planegg/Martinsried (06.10.2020) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, has

Medigene AG: Medigene participates at upcoming virtual conferences

Martinsried/ Munich (28.09.2020) - Medigene AG (FSE: MDG1, Prime Standard) today announces its participation at the following upcoming scientific and investor conferences. Please note that

Medigene AG: Strategic measures including restructuring with extension of cash runway and improved EBITDA

Business news for the stock market

Planegg/Martinsried (22.09.2020) - 22 September 2020. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing

Medigene provides Q2 update and 6M report 2020

Conference call on 7 August 2020 at 2pm CET (Frankfurt) / 8am EDT (New York)

 

Business news for the stock market

 

Martinsried/ Munich (07.08.2020) - Medigene AG (Medigene, FSE: MDG1, Prime

Medigene AG: Medigene expands patent protection of its technologies in key markets, the USA and Europe

Planegg/Martinsried (13.01.2021) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, was

Medigene AG: Participation at upcoming virtual conferences

 

Planegg/Martinsried (21.12.2020) - 21 December 2020. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell

Medigene AG: Dr. Anthony Man appointed to Supervisory Board

 

Planegg/Martinsried (16.12.2020) - The Executive Management Board and the Supervisory Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company

Medigene AG: PRAME expression and HLA genotype screening in AML and MDS patients

Poster at ASH Annual Meeting 2020, 5-8 December 2020

 

Planegg/Martinsried (07.12.2020/16:00) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company f

Medigene AG: Detailed analysis from Medigene's completed Phase I/II DC vaccine in AML patients presented orally at ASH 2020

Planegg/Martinsried (07.12.2020) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, is